Literature DB >> 11391597

Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome.

M Zielenska1, Z M Zhang, K Ng, P Marrano, J Bayani, O C Ramirez, P Sorensen, P Thorner, M Greenberg, J A Squire.   

Abstract

BACKGROUND: The Ewing sarcoma (ES) group of tumors commonly have the t(11;22)(q24;q12) or other rearrangements involving 22q12. In addition to these consistent aberrations, both numeric and structural aberrations have been reported: namely gains of chromosomes 8 and 12, the unbalanced translocation t(1;16), and deletions at the short arm of chromosome 1.
METHODS: To evaluate the frequency and to study the prognostic implications of some of these aberrations in children, the authors performed a pilot study of 26 ES pediatric patients by classic cytogenetics and/or interphase fluorescence in situ hybridization (FISH) and compared these data with clinical parameters.
RESULTS: Gains of chromosomes 8 and 12 were detected, by interphase FISH, in 48% (10 of 21) and 38% (6 of 16) of the tumors, respectively, and this was not significant with respect to treatment response. Statistical analysis revealed that the presence of additional secondary structural chromosomal aberrations was associated with an unfavorable outcome (P = 0.0034 as an independent prognostic value as an unfavorable marker). Presence of metastasis at diagnosis also was found to be associated with poor outcome (P = 0.0131). Spectral karyotyping analysis was shown to facilitate the detection of more complex structural chromosomal aberrations in a representative ES tumor.
CONCLUSIONS: It is important to determine whether additional structural chromosomal aberrations are present in ES tumors because it appears that a more complex karyotype with multiple chromosomal aberrations is associated with poor outcome in ES. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11391597     DOI: 10.1002/1097-0142(20010601)91:11<2156::aid-cncr1244>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma.

Authors:  Mona S Jahromi; Angelica R Putnam; Colleen Druzgal; Jennifer Wright; Holly Spraker-Perlman; Michelle Kinsey; Holly Zhou; Kenneth M Boucher; R Lor Randall; Kevin B Jones; David Lucas; Andrew Rosenberg; Dafydd Thomas; Stephen L Lessnick; Joshua D Schiffman
Journal:  Cancer Genet       Date:  2012 Jul-Aug

Review 2.  Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities.

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

3.  Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines.

Authors:  Lisa J Embree; Mizuki Azuma; Dennis D Hickstein
Journal:  Cancer Res       Date:  2009-05-05       Impact factor: 12.701

4.  Copy Number Alterations and Methylation in Ewing's Sarcoma.

Authors:  Mona S Jahromi; Kevin B Jones; Joshua D Schiffman
Journal:  Sarcoma       Date:  2011-03-15

5.  Guidelines for histopathological specimen examination and diagnostic reporting of primary bone tumours.

Authors:  D Charles Mangham; Nicholas A Athanasou
Journal:  Clin Sarcoma Res       Date:  2011-07-25

6.  Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Authors:  Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor
Journal:  Front Oncol       Date:  2013-06-06       Impact factor: 6.244

7.  The clinical use of biomarkers as prognostic factors in Ewing sarcoma.

Authors:  Annmeik M van Maldegem; Pancras Cw Hogendoorn; Andrew B Hassan
Journal:  Clin Sarcoma Res       Date:  2012-02-08

8.  Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors.

Authors:  Suvi Savola; Arto Klami; Abhishek Tripathi; Tarja Niini; Massimo Serra; Piero Picci; Samuel Kaski; Diana Zambelli; Katia Scotlandi; Sakari Knuutila
Journal:  BMC Cancer       Date:  2009-01-14       Impact factor: 4.430

9.  Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT.

Authors:  S C Brownhill; C Taylor; S A Burchill
Journal:  Br J Cancer       Date:  2007-05-29       Impact factor: 7.640

10.  Prognostic impact of chromosomal aberrations in Ewing tumours.

Authors:  C M Hattinger; U Pötschger; M Tarkkanen; J Squire; M Zielenska; S Kiuru-Kuhlefelt; L Kager; P Thorner; S Knuutila; F K Niggli; P F Ambros; H Gadner; D R Betts
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.